Hakutulokset - Anna Dmoszyńska

Tarkenna hakua
  1. 1
    Metformin – its potential anti-cancer and anti-aging effects

    Metformin – its potential anti-cancer and anti-aging effects Tekijä Monika Podhorecka, Blanca Gil Ibáñez, Anna Dmoszyńska

    Julkaistu 2017
    Hae kokoteksti
    Revisão
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma

    The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma Tekijä Krzysztof Giannopoulos, Wioletta Kamińska, Iwona Hus, Anna Dmoszyńska

    Julkaistu 2012
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells

    Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells Tekijä Barbara Zdzisińska, Agnieszka Bojarska−Junak, Anna Dmoszyńska, Martyna Kandefer‐Szerszeń

    Julkaistu 2008
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity

    Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity Tekijä Iwona Hus, Agnieszka Bojarska−Junak, Sylwia Chocholska, Waldemar Tomczak, Justyna Woś, Anna Dmoszyńska, Jacek Roliński

    Julkaistu 2013
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients

    The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients Tekijä Agnieszka Piechnik, Anna Dmoszyńska, Marcin Omiotek, Radosław Mlak, Małgorzata Kowal, Stephan Stilgenbauer, Lars Bullinger, Krzysztof Giannopoulos

    Julkaistu 2013
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

    Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia Tekijä Peter Hillmen, Aleksander B. Skotnicki, Tadeusz Robak, Branimir Jakšić, Anna Dmoszyńska, Jingyang Wu, Cynthia A. Sirard, Jiřı́ Mayer

    Julkaistu 2007
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia

    The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia Tekijä Iwona Hus, Monika Podhorecka, Agnieszka Bojarska−Junak, Jacek Roliński, Michael Schmitt, Małgorzata Sieklucka, Ewa Wąsik‐Szczepanek, Anna Dmoszyńska

    Julkaistu 2006
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia

    Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia Tekijä Krzysztof Giannopoulos, L Li, Agnieszka Bojarska−Junak, Jacek Roliński, Anna Dmoszyńska, Iwona Hus, Jochen Greiner, C Renner, H. Döhner, Michael Schmitt

    Julkaistu 2006
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia

    Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia Tekijä Maciej Grzywnowicz, Joanna Zaleska, Daniel Mertens, Waldemar Tomczak, Paulina Własiuk, Kamila Kosior, Agnieszka Piechnik, Agnieszka Bojarska−Junak, Anna Dmoszyńska, Krzysztof Giannopoulos

    Julkaistu 2012
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts

    Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts Tekijä Li Li, Krzysztof Giannopoulos, Peter Reinhardt, Jacek Tabarkiewicz, Anita Schmitt, Jochen Greiner, Jacek Roliński, Iwona Hus, Anna Dmoszyńska, Markus Wiesneth, Michael Schmitt

    Julkaistu 2006
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma

    Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma Tekijä Marek Hus, Norbert Grząśko, Marta Szostek, Andrzej Pluta, Grzegorz Helbig, Dariusz Woszczyk, Maria Cioch, Dariusz Jawniak, Wojciech Legieć, Marta Morawska, Justyna Kozińska, Piotr Waciński, Anna Dmoszyńska

    Julkaistu 2011
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia

    Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia Tekijä Thomas J. Walsh, Hedy Teppler, Gerald R. Donowitz, Johan Maertens, Lindsey R. Baden, Anna Dmoszyńska, Oliver A. Cornely, Michael Bourque, Robert Lupinacci, Carole A. Sable, Ben E. dePauw

    Julkaistu 2004
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

    Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia Tekijä Carlo Gambacorti‐Passerini, Jorge E. Cortés, Jeff H. Lipton, Anna Dmoszyńska, Raymond Wong, Victor Rossiev, Dmitri Pavlov, Karin Gogat Marchant, Ladan Duvillié, Navin Khattry, Hagop M. Kantarjian, Tim H. Brümmendorf

    Julkaistu 2014
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  14. 14
    Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

    Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multipl... Tekijä Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hájek, Andrew Spencer, Tadeusz Robak, Anna Dmoszyńska, Noemi Horvath, Ivan Špıčka, Heather J. Sutherland, А. Н. Суворов, Liang Xiu, Andrew Cakana, Trilok Parekh, Jesús F. San Miguel

    Julkaistu 2016
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  15. 15
    Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma Tekijä Meletios Α. Dimopoulos, Andrew Spencer, Michael Attal, H. Miles Prince, Jean‐Luc Harousseau, Anna Dmoszyńska, Jesús F. San Miguel, Andrzej Hellmann, Thierry Façon, Robin Foà, Alessandro Corso, Zvenyslava Masliak, Marta Olesnyckyj, Zhinuan Yu, John Patin, Jerome B. Zeldis, Robert Knight

    Julkaistu 2007
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  16. 16
    Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

    Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment... Tekijä Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska, Agnieszka Wierzbowska, Grzegorz Mazur, Jiří Mayer, Jyh-Pyng Gau, Wen‐Chien Chou, Rena Buckstein, Jaroslav Čermák, Ching-Yuan Kuo, Albert Oriol, Farhad Ravandi, Stefan Faderl, Jacques Delaunay, Daniel Lysák, Mark D. Minden, Christopher Arthur

    Julkaistu 2012
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  17. 17
    Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study)

    Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Po... Tekijä Tadeusz Robak, Krzysztof Jamroziak, Joanna Góra‐Tybor, Beata Stella‐Hołowiecka, L Konopka, B. Ceglarek, Krzysztof Warzocha, Ilona Seferyńska, Jarosław Piszcz, Małgorzata Całbecka, Aleksandra Kostyra, Jadwiga Dwilewicz‐Trojaczek, Anna Dmoszyńska, Krystyna Zawilska, Andrzej Hellmann, A Zduńczyk, S Potoczek, Magdalena Piotrowska, Krzysztof Lewandowski, Jerzy Z. Błoński

    Julkaistu 2010
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  18. 18
    Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma

    Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma Tekijä Heinz Ludwig, Luísa Viterbo, Richard Greil, Tamás Masszi, Ivan Špıčka, Ofer Shpilberg, Roman Hájek, Anna Dmoszyńska, Bruno Paiva, María‐Belén Vidriales, Graça Esteves, Anne Marie Stoppa, Don Robinson, Deborah Ricci, Andrew Cakana, Christopher Enny, Huaibao Feng, Helgi van de Velde, Jean‐Luc Harousseau

    Julkaistu 2012
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  19. 19
    Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

    Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improve... Tekijä Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hájek, Andrew Spencer, Jesús F. San Miguel, Tadeusz Robak, Anna Dmoszyńska, Noemi Horvath, Ivan Špıčka, Heather J. Sutherland, А. Н. Суворов, Sen Hong Zhuang, Trilok Parekh, Liang Xiu, Zhilong Yuan, Wayne Rackoff, Jean‐Luc Harousseau

    Julkaistu 2007
    Hae kokoteksti Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:
  20. 20
    Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

    Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Le... Tekijä Tadeusz Robak, Anna Dmoszyńska, Philippe Solal‐Céligny, Krzysztof Warzocha, Javier Loscertales, John Catalano, B. V. Аfanasiev, Loree Larratt, Christian H. Geisler, Marco Montillo, Ilya Zyuzgin, Peter Ganly, Caroline Dartigeas, András Rosta, Jörg Maurer, Myriam Mendila, M. Wayne Saville, Nancy Valente, Michael Wenger, Moiseev Si

    Julkaistu 2010
    Hae kokoteksti
    Artigo
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: